ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
miR-199a Knockdown Alleviates Insulin Resistance and Inflammation by Targeting DDIT4 via the PI3K/AKT Pathway in vitro and in vivo.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Insulin resistance (IR) is a pivotal pathological feature in the development of type 2 diabetes mellitus (T2DM). MicroRNA-199a (miR-199a) has been implicated in various metabolic disorders, but its precise role and mechanism in hepatic IR remain largely unexplored. This study aimed to investigate the role of miR-199a in IR and inflammation and to determine whether its effects are mediated through DDIT4 and the PI3K/AKT pathway. Methods: An in vitro IR model was established in HepG2 cells using palmitic acid, and an in vivo T2DM model was induced in mice using a high-fat diet combined with streptozotocin injection. Functional assays, including glucose uptake and ELISA, were employed to assess metabolic and inflammatory responses. The interaction between miR-199a and its putative target, DDIT4, was validated by luciferase reporter and RNA immunoprecipitation assays. Key proteins in the PI3K/AKT signaling pathway were analyzed by Western blotting. Results: We found that miR-199a was significantly upregulated, while DDIT4 was downregulated in both IR HepG2 cells and diabetic mice. Mechanistically, we identified DDIT4 as a direct target of miR-199a. Knockdown of miR-199a ameliorated insulin resistance and suppressed inflammation, whereas concomitant depletion of DDIT4 abolished these protective effects. Furthermore, miR-199a inhibition activated the PI3K/AKT pathway, as evidenced by increased phosphorylation of PI3K, AKT, and AS160, and decreased phosphorylation of FOXO1. These signaling changes were also dependent on DDIT4. In vivo, inhibition of miR-199a improved glucose homeostasis, attenuated systemic inflammation, and activated pancreatic PI3K/AKT signaling in T2DM mice. Conclusion: Our findings reveal a novel miR-199a/DDIT4 axis that regulates insulin sensitivity and inflammation via the PI3K/AKT pathway, suggesting miR-199a as a potential therapeutic target for T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.